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Antidepressants generally inhibit REM sleep. This effect is
often considered to be a crucial feature of these drugs.
Trimipramine, however, is a tricyclic antidepressant which
does not inhibit REM sleep in rats (Khazan and Brown,
1970; Wassennan and Khazan, 1971). This result could be
confirmed in man: Dunleavy et al. (1972) administered this
drug to two healthy volunteers and found no alteration of
REM sleep. In our present study we examined the action of
trimipramine on sleep in patients with major depressive dis-
order. We were especially interested in the effect on REM
sleep parameters. In order to elucidate the mode of action
of this 'drug, we investigated, in addition, the question of
whether the effect of trimipramine on prolactin, human
growth hormone, and cortisol resembled that of other anti-
depressants.
Methods
We examined 10 patients (2 male, 8 female) with the diagnosis of a
major depressive disorder according to the RDC; 7 of them (1 male,
6 female) fulfilled thc criteria for the endogenous subtype. The
mean age was 43.0 ± 13.3 years, the mean score in the Hamilton
Depression Scale (21 items) before treatment was 23.8 ± 5.2. All
patients were free from any psychoactive medication, except chlo-
raid urate, for at least seven days before sleep recordings took place. Af-
ter an adaptation night, sleep was recorded in the night preceding the
first medication and in the 2nd, 11 th, and 21 st nights of treatment. We
administered 75 mg trimipramine on the first day and 100 mg on the
second day. The dose was augmented stepwise, and from the 6th day
on the patients received 200 mg per day.
Ratings of depressive symptomatology were performed by means
of the Hamilton Depression Scale (21 items) on the days before
each sleep record ing.
In an additional study with healthy subjects, we examined the ef·
fect of trimipramine on neuroendocrine parameters. We administer-
ed a single ora I dose of 75 mg trimipramine to 8 healthy volun teers
(5 male, 3 female); the mean age was 25.1 ± 4.4 years. Blood sam-
pIes were taken at half-hour intervals, two of thpm before and six
after the administration of the drug. Prolactin, human growth
hormone, and cortisol were measured by radioimmunoassay.
Results
I. Sieep EEG
Table I summarizes the effect of trimipramine on several
sleep parameters. From the 11th day on, sleep period time
and sleep efficiency are significantly increased, and sleep
latency is shortened. There is no influence on slow wave
sleep. REM sleep time is significantly increased with regard
to the mean baseline score (which, however, appears to be
abnormally low in our sampie). The first REM period is
lengthened in the beginning of treatment. REM latency is
significantly longer on the 11th day only. There seems to
be no effect on REM density.
2. Psychopathology
Taking areduction of at least 50 %of the baseline Hamil-
ton score as a response criterion, 5 patients (3 endogenous
and 2 non-endogenous) responded to treatment with trimi-
pramine. The improvement is most clearly reflected by the
changes in the insomnia and anxiety items. This finding cor-
responds weIl with the results of the sleep recordings.
3. Hormones
Figure 1 demonstrates the effect of a single oral dose of
75 mg trimipramine on the plasma levels of prolactin,
human growth hormone and cortisol in healthy probands.
There is a remarkable effect on the mean prolactin level:
6 of the 8 probands exhibit an increase of more than 100 %
of the baseline plasma prolactin level three hours after the
administration of the drug. The plasma levels of human
growth hormone and cortisol are not elevated (as the blood
samplings took place in the aftemoon, cortisollevels de-
cline according to their usual circadian rhythm).
Discussion
In contrast to the REM suppressing action of antidepressant
drugs in general, we found trimipramine to increase the per-
centage of REM sleep time. Regarding the abnormally low
mean baseline score of this variable (which is due to a large
proportion of patients with very severely disturbed sleep in
our sampie), this result could be interpreted as a normaliza-
tion of REM sleep time, in accord with the general improve-
ment of sleep during treatment. In some patients, there was
even a stimulation of REM sleep beyond normal scores. Our
findings, thus, support the results from other studies men-
tioned before that there is no REM suppressing effect of
trimipramine, and even point to a REM stimulating effect
of this drug.
This has some implications conceming the importance of
REM sleep suppression for an tidepressant action. Studies
by Gillin et al. (1978) and Kupfer et al. (1980) which show
a correlation between the initial REM suppression of a drug
and its antidepressant effect and Vogel's (1975,1980) ex-
periments which demonstrate that the antidepressant effect
of REM sleep deprivation support the hypothesis that REM
suppression is an important factor, or even aprerequisite,
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Table 1 Sleep parameters: mean scores and standard deviations; Significant changes from
baseline: • p .;; 0.05, *. p .;; 0.01 (Wilcoxon's test, two-tailed)
Fig. 1 Effect of a single oral dose of 75 mg trimipramine on plasma
levels of prolactin, human growth hormone and cortisol in healthy
probands.
roleptics. There are several other similarities to neuroleptic
drugs, and the observed clinical effect of trimipramine has
some features in common with those of some sedative
neuroleptics, e. g. levomepromazine which has the same
side chain as trimipramine, and thioridazine which stimu-
lates REM sleep, according to Kaies et al. (1974). Both
these drugs are reported to have an antidepressant actioll
besides the neuroleptic oiJe. Trimipramine resembles them
in possessing thymoleptic properties without being a ty-
pical antidepressant. This is compatible with the assump-
tion that certain sedative neuroleptics may be useful in the
















2nd day of 11 th day of 21st day of
treatment treatment treatment
397.8 ± 41.3 405,4 ± 42.2' 414.3 ± 25.S*
86.0 ± 9.7 88.2 ± 9.S· 90.1 ± 9.1"
22.3 ± 22.7 15,4 ± 14.7* 12.8 ± 6.9*
7.7 ± 9.8 11.3 ± 12.1 8.5 ± 8.5
22.9 ± 4.8** 19.6 ± 3,4* 20.9 ± 5.3*
38.8 ± 39.6 70.2 ± 34.1* 56.0 ± 20.3
30.9 ± 19.9* 23.7 ± 16.9 19.7 ± 17.6
----
32.3 ± 11.8 41.3 ± 13.3 38,4 ± 10.1
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Sieep period time 347.8 ± 103.6
Sieep efficiency 69.2 ± 30.6
Sieep latency 46,4 ± 73.5
Siow wave sleep
time (%) 12.4 ± 12.8
REM sleep time (%) 14.3 ± 5.3
REM latency 44.8 ± 31.0
Duration of
1st REM period 12.3 ± 10.6




for antidepressant action. Our results seem to contradict
this hypothesis.
The absence of REM sleep suppression during acute treat-
ment with trimipramine suggests that the mode of action of
this drug may be different from that of other antidepres-
sants. Several pharmacological studies demonstrate more
atypical features of this drug. There is no effect on beta-
adrenergic receptors (Hauser et al., 1985), only a very weak
effect on norepinephrine and serotonine re-uptake in the
rat (Richelson and Pfenning, 1984), and no effect on amine
re-uptake in man (Gastpar, personal communication).
Waldmeier (1982) demonstrated a dopamine receptor
blocking property of trimipramine. Our findings conceming
the effect on prolactin, human growth hormone, and corti-
sol also reveal an atypical response pattern in comparison
with other antidepressan ts. It rather resembles that of neu-
